Provides pain relief for more than 30 conditions, including chronic back pain, arthritis, and sports injuries
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
Healthcare and insurance are not parallel systems; they are interdependent pillars of patient trust
The NP resin portfolio, indicated by its UL746G-certified prefix, equips manufacturers across industries to meet increasingly stringent regulatory and performance standards
The reform is set to modernise how medicines are developed, authorised, and made available across the EU
The Phase-2b study is a randomized, double-blind, placebo-controlled trial that will enroll approximately 195 patients across 35 sites in the USA
The investigational therapy uses SteadyTeq, a proprietary copolymer technology from Medincell designed to release olanzapine steadily over time
The new site will produce next-generation synthetic medicine active pharmaceutical ingredients
_Logo_256_384.png){kind=logo}
The Vital Shape panels provide tiered assessments to detect obesity-related risks early
Subscribe To Our Newsletter & Stay Updated
